Prognostic Significance Of Circulating Tumour Biomarkers In Patients Treated With Curative-Intent Radiotherapy For Nsclc

Grant number: 1104139 | Funding period: 2016 - 2020



More than 50% of cancer patients in Australia receive radiotherapy but many later die from distant metastases. This study of circulating biomarkers (tumour cells and DNA in the bloodstream) builds on evidence from research at Peter Mac showing that some lung cancers might spread during treatment with radiotherapy that would otherwise be curative. This study will help identify cancer patients at high risk of secondary cancers and could allow us to modify treatments to prevent them.